competition in Brazil’s pharma and healthcare sector is becoming increasingly intense. The
deceleration of the domestic drug market has propelled the pharmaceutical companies operating in
the country to search for scale and efficiency gains through organic growth, acquisitions and
internationalisation of their operations. The opening of the healthcare market to foreign investors in
January 2015 also unleashed a consolidation trend, triggered by the entry of both strategic and
institutional investors. Given the deficiencies in the provision of quality health services, healthcare
will remain the subsector with the highest growth potential in the medium term.